Earnings Releases·Nov 9, 2026, 9:00 AM ET

United-Guardian — Q3 2026 Earnings Summary

Q3 net sales surged 54% year-over-year to $3.49 million, while net income jumped 247% to $930,912 ($0.20 per share); nine-month net sales rose 25% to $9.48 million with net income increasing 70% to $2.48 million ($0.54 per share).
Segment performance was driven by a 29% pharmaceutical sales increase led by Renacidin, a 187% surge in cosmetic ingredient sales, and a 20% rise in medical lubricants.
Future outlook includes evaluating marketing for Renacidin and launching a new personal care product in late-stage development early next year.
Nine-month results included $339,493 in settlement income and an $8,310 gain on asset sale, with no comparable amounts in the prior year.